- Morepen Laboratories has completed its first commercial dispatch worth approximately ₹50 crore ($5.8 million) under its previously announced ₹825 crore CDMO mandate.
- The company expects additional supplies of around ₹225 crore ($26.2 million) during Q2 FY2026–27 and plans to expand its reactor capacity to approximately 600 KL by the end of Q2.
Morepen Laboratories Limited has completed its first commercial dispatch under its previously announced ₹825 crore CDMO mandate, marking the transition of the program from validation and qualification to commercial execution. The first shipment, valued at approximately ₹50 crore, was dispatched during the first quarter of FY2026–27.
According to the company, the program is expected to expand further in the second quarter of FY2026–27, with additional supplies worth approximately ₹225 crore, subject to customer schedules and regulatory and commercial requirements. The commercial supply follows collaboration with the customer on validation, manufacturing readiness, and supply chain planning.
Morepen said it is continuing to strengthen its manufacturing infrastructure to support additional contract manufacturing opportunities. The company expects its total reactor capacity to reach approximately 600 KL by the end of the second quarter, with further expansion planned to 800 KL and 1,000 KL in subsequent phases.
“This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities.”
Sanjay Suri, Managing Director of Morepen Laboratories Limited
The company said the start of commercial supplies under the mandate supports its strategy to build a scalable CDMO platform, strengthen customer partnerships, and participate in long-term global manufacturing programs.
